TRVN
$0.82
Trevena
($.04)
(4.65%)
TRVN
Earnings Whisper ®
N/A
3rd Quarter September 2018
Consensus:  ($0.16)
Revenue:  $3.00 Mil
Tuesday
Nov 6
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, August 2, 2018

What do you expect when TRVN reports earnings?
Beat
Meet
Miss

Where is TRVN's stock price going from here?
Up
Flat
Down
Stock chart of TRVN
Analysts
Summary of analysts' recommendations for TRVN
Score
Grade
Pivots
Resistance
$0.98
$0.93
$0.88

$0.83

Support
$0.78
$0.73
$0.68
Tweet
Growth
Description
Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.
Peers
CelgeneRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalEndo International plcJohnson & JohnsonUltragenyx PharmaceuticalBristol-Myers SquibbEli LillyMylan